Verrica Pharmaceuticals (VRCA) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Verrica Pharmaceuticals (NASDAQ: VRCA):

• 10/21/2024 – Verrica Pharmaceuticals had its price target lowered by analysts at TD Cowen from $15.00 to $10.00. They now have a “buy” rating on the stock.
• 10/4/2024 – Verrica Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $13.00 to $11.00. They now have an “outperform” rating on the stock.
• 10/3/2024 – Verrica Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
• 10/2/2024 – Verrica Pharmaceuticals had its “hold” rating reaffirmed by analysts at Brookline Capital Management.

Verrica Pharmaceuticals Trading Down 1.9 %

Verrica Pharmaceuticals stock traded down $0.03 during midday trading on Monday, reaching $1.57. The stock had a trading volume of 332,698 shares, compared to its average volume of 437,165. The company has a quick ratio of 2.23, a current ratio of 2.36 and a debt-to-equity ratio of 29.58. The firm has a market cap of $66.60 million, a price-to-earnings ratio of -0.90 and a beta of 1.45. Verrica Pharmaceuticals Inc. has a 52-week low of $1.04 and a 52-week high of $11.41. The company has a fifty day moving average of $2.09 and a 200 day moving average of $5.63.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $4.70 million. On average, analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Verrica Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after purchasing an additional 7,609 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Verrica Pharmaceuticals by 8.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock worth $428,000 after buying an additional 4,393 shares in the last quarter. Key Financial Inc purchased a new position in shares of Verrica Pharmaceuticals during the second quarter valued at $69,000. Rhumbline Advisers lifted its stake in Verrica Pharmaceuticals by 20.4% in the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock worth $194,000 after acquiring an additional 4,514 shares during the period. Finally, Quest Partners LLC bought a new position in Verrica Pharmaceuticals during the 2nd quarter worth about $50,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.